entity-batch: update 1 entities

- Applied 1 entity operations from queue
- Files: domains/health/semaglutide-cardiovascular-benefit-is-67-percent-independent-of-weight-loss-with-inflammation-as-primary-mediator.md

Pentagon-Agent: Epimetheus <968B2991-E2DF-4006-B962-F5B0A0CC8ACA>

domains/health/semaglutide-cardiovascular-benefit-is-67-percent-independent-of-weight-loss-with-inflammation-as-primary-mediator.md

@@ -23,6 +23,21 @@ The convergence of two independent analyses on 67-69% weight-independence is str
 
 This has major implications: (1) the drug should benefit patients across the BMI spectrum, not just high-BMI populations, (2) access barriers are blocking a drug that works via anti-inflammatory mechanisms that address SDOH-generated CVD risk, not just metabolic pathways, and (3) the therapeutic framing needs to shift from 'obesity drug with CV benefits' to 'CV drug that also treats obesity.'
 
+
+### Auto-enrichment (near-duplicate conversion, similarity=1.00)
+*Source: PR #2120 — "semaglutide cardiovascular benefit is 67 percent independent of weight loss with inflammation as primary mediator"*
+*Auto-converted by substantive fixer. Review: revert if this evidence doesn't belong here.*
+
+### Additional Evidence (confirm)
+*Source: [[2026-03-30-lancet-select-adiposity-independent-cv-outcomes-2025]] | Added: 2026-03-30*
+
+SELECT trial prespecified analysis (N=17,604) published in The Lancet November 2025 confirms ~67% of MACE reduction is independent of weight/adiposity changes. Treatment effect was consistent across ALL baseline BMI and waist circumference categories with no evidence of heterogeneity. Time-varying weight loss analysis showed 'no evidence that the treatment effect of semaglutide was mediated by time-varying weight loss.' Only ~33% of benefit explained by early waist circumference reductions. This is stronger evidence than the ESC 2024 abstract because it's a prespecified (not exploratory) analysis from the definitive SELECT publication.
+
+### Additional Evidence (confirm)
+*Source: [[2026-03-30-lancet-select-adiposity-independent-cv-outcomes-2025]] | Added: 2026-03-30*
+
+ESC 2024 mediation analysis (Colhoun/Lincoff) found hsCRP (inflammation marker) mediated 42.1% of CV benefit while body weight mediated only 19.5%. Joint mediation of all measured metabolic factors was 31.4% (95% CI: -30.1% to 143.6%), leaving ~68.6% of benefit unexplained by adiposity or standard metabolic parameters. The convergence between this analysis (68.6% unexplained) and the Lancet prespecified analysis (67% weight-independent) from independent methodologies strengthens the anti-inflammatory mechanism hypothesis.
+
 ---
 
 ### Additional Evidence (confirm)